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of DCs. exposure of both murine spleen-derived and 
human monocyte-derived DCs to ansamitocin P3 trig-
gered up-regulation of maturation markers and production 
of pro-inflammatory cytokines, resulting in an enhanced 
T cell stimulatory capacity. local administration of 
ansamitocin P3 induced maturation of skin langerhans 
cells in vivo and promoted antigen uptake and extensive 
homing of tumor-resident DCs to tumor-draining lymph 
nodes. When used as an adjuvant in a specific vaccination 
approach, ansamitocin P3 dramatically increased activa-
tion of antigen-specific T cells. Finally, we demonstrate 
that ansamitocin P3, due to its immunomodulatory prop-
erties, acts in synergy with antibody-mediated blockade 
of the T cell inhibitory receptors PD-1 and Ctla-4. the 
combination treatment was most effective and induced 
durable growth inhibition of established tumors. Mecha-
nistically, we observed a reduced regulatory T cell fre-
quency and improved T cell effector function at the tumor 
site. taken together, our study unravels an immune-based 
anti-tumor mechanism exploited by microtubule-depo-
lymerizing agents, including ansamitocin P3, and paves 
the way for future clinical trials combining this class of 
agents with immunotherapy.
Keywords anti-tumor immunity · Dendritic cell 
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Introduction
recent advances in understanding the anti-tumor immune 
response have led to major improvements in the field 
of cancer immunotherapy [1]. In particular, blocking 
immune checkpoints with monoclonal antibodies such 
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as anti-Ctla-4 and anti-PD-1 has emerged as promising 
strategy that mediates clinically significant responses in a 
broad variety of cancer types [2, 3]. Combining conven-
tional chemotherapy with immunotherapies may further 
improve efficacy [4, 5]. However, many chemotherapeu-
tic agents interfere with anti-tumor immune responses by 
impairing the clonal expansion of effector lymphocytes or 
by disturbing the homeostasis of immune cells [6]. this 
is not surprising, as classical chemotherapeutic agents 
were originally selected based on their ability to interfere 
with metabolic processes, Dna maintenance, gene tran-
scription as well as rna and protein biosynthesis. On the 
other side, the tumor microenvironment itself may actively 
impede effector cell function, thereby limiting the effi-
cacy of immune-based therapies [7]. With regard to this, 
it has recently become evident that some chemotherapeu-
tic agents and molecular targeted therapies are capable 
of interfering with tumor–host interactions, thus mediat-
ing therapeutic effects by promoting anti-tumor immune 
responses [8]. these therapies may act on tumor cells by 
modulating their propensity to elicit anti-tumor immune 
responses; or alternatively, immune effector cells may 
be stimulated, either directly or by relieving immunosup-
pressive mechanisms within the tumor microenvironment. 
therefore, the combination of selected chemotherapy part-
ners with immunotherapies has great clinical potential, but 
requires a deeper understanding of the immune-promoting 
nature of these agents.
Dendritic cells (DCs) are specialized antigen-presenting 
cells with a pivotal role in the initiation and maintenance 
of anti-tumor immune responses. their unique ability to 
induce primary immune responses makes them ideal can-
didates for generating therapeutic immunity against cancer 
[9]. Of note, activated (mature) DCs promote the differen-
tiation of antigen-specific T cells into T cells that execute 
broad and efficient effector functions; non-activated (imma-
ture) DCs, however, may rather induce a state of tolerance 
through either deletion of T cells or differentiation of reg-
ulatory/suppressor T cells. Hallmarks of DC maturation 
include a limited capacity to efficiently capture antigens, 
increased expression of surface MHC class II and costimu-
latory molecules, and the ability to secrete cytokines and 
to migrate into draining lymph nodes. Importantly, tumors 
may prevent the generation of sustained anti-tumor immu-
nity by inducing DC dysfunction through a variety of 
mechanisms [10]. along with the identification of chemo-
therapeutic agents capable of triggering immunogenic cell 
death, DCs have been recognized as critical players in 
therapy-induced anti-tumor immunosurveillance. Particu-
larly, anthracyclines, oxaliplatin, and mafosfamide are able 
to induce a series of molecular signatures on dying tumor 
cells, which can promote DC-mediated anti-tumor immu-
nity via such endogenous vaccination [11]. a different, 
equally attractive therapeutic scenario harnesses the poten-
tial of anticancer agents to directly promote DC differen-
tiation and maturation, even in the absence of signals from 
dying tumor cells. Mechanistically, these agents reinstate 
immunosurveillance by driving a distinct DC maturation 
program, besides their ability to potently inhibit tumor cell 
growth. Few studies have investigated the pharmacological 
effect of different anti-tumor agents on DC function to date. 
recent studies have identified cytotoxic agents including 
anthracyclines [12] and the mitotic spindle inhibitor vin-
blastine as potent activators of DC maturation [13–15]. On 
the other side, some anti-tumor therapeutics do block DC 
maturation and therefore antagonize anti-tumor immunity. 
Such inhibitory effects on DC function are seen with the 
estrogen receptor modulators tamoxifen and raloxifene [16] 
and the anti-angiogenic tyrosine kinase inhibitor sorafenib, 
but not sunitinib [17].
to investigate whether the effect of specific chemo-
therapeutics on DC maturation is related to their com-
pound class, we tested a panel of 21 cytotoxic compounds 
of distinct classes for their ability to induce activation of 
murine and human DCs. Consistent with previous data 
on vinblastine and colchicine [13–15], all tested micro-
tubule-destabilizing compounds were able to induce DC 
stimulation, whereas microtubule-stabilizing compounds, 
such as the taxanes, did not exert this effect. among 
microtubule-destabilizing agents, the maytansinoid 
ansamitocin P3 was identified as the most potent inducer 
of DC maturation, which resulted in augmentation of anti-
tumor immunity in tumor-bearing hosts. By combining 
T cell co-inhibitory blockade with ansamitocin P3 treat-
ment, we were able to induce rejection of tumors and to 
characterize the cellular and molecular mechanisms driv-
ing this response.
Material and methods
reagents and antibodies
twenty-one anticancer agents of different classes were 
tested (supplementary table 1). Drugs were dissolved in 
DMSO (10 mmol/l) and tested at various concentrations 
with a final maximum DMSO concentration of 0.5 %. 
endotoxin-free ovalbumin (OVa) protein (endograde) 
was purchased from Hyglos Biotechnology, germany. 
escherichia coli 026:B6 lipopolysaccharide (lPS), FItC-
conjugated dextran, and Corynebacterium diphtheriae diph-
theria toxin (Dt) were purchased from Millipore, t4 pep-
tide (SIItFeKl) from eurogentec, and OVa323–339 peptide 
from Peptides and elephants. α-Ctla-4 (clone 9D9) and 
α-PD1 (clone rMP1-14) antibodies and matched isotype 
controls for in vivo treatment were produced by BioXCell.
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Cell lines
the immature mouse DC cell line SP37a3 (Merck Kgaa, 
[18]) was cultured in Iscove’s modified Dulbecco’s medium 
(IMDM; Sigma) supplemented with 10 % heat-inactivated 
and endotoxin-tested FBS (Paa), sodium pyruvate (gibco), 
penicillin/streptomycin, l-glutamine mix (gibco), eagle’s 
minimum essential medium (MeM), nonessential amino 
acids (Sigma), Ciproxin (Bayer), and 0.05 mM 2-mercap-
toethanol (gibco). IMDM complete medium was supple-
mented with 20 ng/ml recombinant mouse gM-CSF and 
20 ng/ml recombinant mouse M-CSF (both Peprotech). 
the murine tumor cell line eg-7 was obtained from atCC 
(Virginia). Murine MC38 tumor cells were provided by 
Mark Smyth (Peter MacCallum Cancer Centre, Melbourne, 
aU). 3ll-thy1.1-OVa cells were provided by Doug-
las t. Fearon (Cancer research UK Centre, Cambridge, 
UK). Cells were cultured in Dulbecco’s modified eagle’s 
medium (DMeM) with glutamax (gibco) supplemented 
with 10 % heat-inactivated FBS, sodium pyruvate, peni-
cillin/streptomycin, l-glutamine mix, MeM, nonessential 
amino acids, Ciproxin and 0.05 mM 2-mercaptoethanol.
Mice
C57Bl/6 mice were obtained from Charles river labora-
tories (Wilmington, Ma) and Ot-II tCr transgenic mice 
from J. Pieters (Biozentrum, University of Basel, Switzer-
land). Ot-I tCr, recombination activating gene 2 deficient 
(rag2−/−), interferon-γ-receptor deficient (IFn-γr−/−), 
CD11c-diphtheria toxin receptor (Dtr)/gFP trans-
genic mice, and C57Bl/6-ly5.1 mice were bred in-house 
(Department of Biomedicine, University Hospital Basel, 
Switzerland). all animals were housed under specific path-
ogen-free conditions and in accordance with Swiss federal 
regulations.
generation of bone marrow DCs
Bone marrow cells (2 × 106/10 ml complete DMeM 
medium) from C57Bl/6 Wt mice were cultured in the 
presence of 20 ng/ml recombinant murine gM-CSF 
(Peprotech) and were activated at day 7 of culture. after 
24-h stimulation, the DC phenotype was assessed by flow 
cytometry and DCs were used in co-culture assays.
activation of human and murine DCs in vitro
Peripheral blood mononuclear cells (PBMCs) from healthy 
donors (Blood transfusion Center, University Hospital 
Basel) were isolated from buffy coats by density gradi-
ent separation (Histopaque 1077, Sigma). CD14+ mono-
cytes were purified with anti-CD14-coated microbeads 
(Miltenyi Biotec, germany) and induced to differentiate to 
DCs in a 5- to 6-day culture in complete rPMI 1640 sup-
plemented with 10 % heat-inactivated and endotoxin-tested 
FBS (Paa), sodium pyruvate, penicillin/streptomycin, 
l-glutamine mix, MeM nonessential amino acids, 0.05 mM 
2-mercaptoethanol, 50 ng/ml gM-CSF, and 250 U/ml 
recombinant human interleukin 4 (rhIl-4; Peprotech). DC 
purity and maturation were routinely checked by means of 
flow cytometric analysis.
Murine SP37a3 DCs and day 6 human monocyte-
derived DCs (moDCs) were incubated (6 × 104 cells/
well) with cytotoxic compounds (0.1 μM) or lPS (500 ng/
ml) as positive control. after 24 h, the DC phenotype was 
assessed by flow cytometry. Dead cells were excluded by 
Sytoxgreen® (Invitrogen) staining.
Cytokine detection
Il-1β, Il-6, and Il-12 in supernatants of murine DC cul-
tures were detected by standard sandwich elISa proce-
dures using commercially available kits (eBioscience). 
Furthermore, cytokine secretion of SP37a3 DCs or bone 
marrow-derived DCs (BMDCs) was characterized by flow 
cytometric analysis. For this purpose, cells were cultured in 
the presence of ansamitocin P3 (0.01 μM) or lPS (500 ng/
ml) for 20 h (Il-12), 15 h (Il-6), or 6 h (Il-1β). Brefel-
din a was added for the whole incubation time (Il-1β 
and Il-6) or for the last 6 h of culture (Il-12). Cell sur-
face staining of MHCII and CD11c was performed follow-
ing fixation, permeabilization, and intracellular cytokine 
staining.
In situ maturation of skin langerhans cells
twenty μl ansamitocin P3 (4 μg/mouse) or PBS was 
injected intradermally (i.d.) into the ears of C57Bl/6 mice 
(three mice/group, two ears/point). ear skin specimens 
were harvested after 24 h, and epidermal sheets were sepa-
rated and digested with accutase (Paa), collagenase IV 
(Worthington), hyaluronidase (Sigma), and Dnase type 
IV (Sigma) for flow cytometric analysis. Single-cell sus-
pensions were stained with anti-CD45, anti-CD11c, anti-
MHC-II, and anti-CD86 antibodies (BD Biosciences). 
Dead cells were excluded with SytoxBlue® (Invitrogen) 
staining. For immunofluorescence, epidermal sheets were 
prepared as previously described [19], stained overnight 
with anti-MHC-II and anti-CD86 antibodies, and analyzed 
using an Olympus BX61 fluorescence microscope.
In vitro stimulation of OVa-specific Ot-I and Ot-II t cells
SP37a3 DCs or BMDCs (day 7) were pulsed with OVa 
full-length protein (0.1 mg/ml) for 1 h and activated 
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with 0.01 μM ansamitocin P3 (24 h). activated DCs were 
washed and co-cultured with CD8+ Ot-I or CD4+ Ot-II T 
cells purified from lymph nodes and spleens of Ot-I and 
Ot-II transgenic mice, respectively. T cells were isolated 
using T cell enrichment kit (easySep, Stemcell technol-
ogy). CD8+ and CD4+ T cells were loaded with the pro-
liferation dye eFluor670 (eBioscience) prior to co-cul-
ture. Proliferation was assessed after 3 days using flow 
cytometry.
tracking of DC migration to tumor-draining lns
2 × 105 eg-7 tumor cells were injected s.c. into the right 
flank of C57Bl/6 mice. When tumors reached an average 
size of size of approximately 50–60 mm3, ansamitocin P3 
(4 μg/mouse) or PBS (control) together with FItC-conju-
gated dextran (100 μg/mouse; Sigma) was injected intra-
tumorally. tumor-draining and non-draining lns were 
isolated after 48 h, and single-cell suspensions were ana-
lyzed for CD45, CD11c, CD11b, MHC-II, and CD86 by 
flow cytometry. Dead cells were excluded by SytoxBlue® 
staining.
In vivo activation of antigen-specific Ot-I t and Ot-II cells
CD8+ or CD4+ T cells from lns and spleen of naïve Ot-I 
or Ot-II transgenic mice (ly5.2), respectively, were labeled 
with eFluor670 and adoptively transferred into C57Bl/6-
ly5.1 mice (2 × 106 cells/mouse). twenty-four hour 
later, mice were immunized with 25 μg OVa-t4 peptide 
(SIItFeKl; low-affinity variant of SIInFeKl [20]) and 
OVa323–339 peptide together with ansamitocin P3 (4 μg/
mouse) or lPS (25 μg/mouse) via tail-base injection. Sin-
gle-cell suspensions from “vaccine”-draining inguinal lns 
were prepared 3 days after transfer, and proliferation of 
Ot-I CD8+ as well as Ot-II CD4+ T cells was assessed by 
flow cytometry.
Human mixed lymphocyte reaction
Human moDCs were incubated with ansamitocin P3 (1 nM) 
or lPS (500 ng/ml) during differentiation (d4–d6), washed, 
irradiated (30 gy), and plated in rPMI1640 supplemented 
with 10 % human serum (aB). CD8+ T cells from healthy 
donors were purified as described [21] and labeled with 
eFluor670. allogeneic CD8+ T cells were added (day 6) to 
cultures of activated DCs (DC/t ratio of 1:25). T cell prolif-
eration was assessed after 4 days by flow cytometry.
tumor challenge and therapeutic protocol
Seven- to ten-week-old mice were injected subcutaneously 
(s.c.) into the right flank with 2.5–5 × 105 tumor cells in 
100 μl phenol red-free DMeM (gibco). Wt C57Bl/6, 
rag2−/−, and IFn-γr−/− mice bearing s.c. eg-7 tumors 
received intratumoral injections of ansamitocin P3 (0.3 mg/
kg) or vehicle (PBS) on day 10. Wt and CD11c-Dtr/gFP 
mice bearing s.c. 3ll-thy1.1-OVa tumors were treated 
i.v. with ansamitocin P3 (0.3 mg/kg) on day 16. Dt (4 ng/g 
body weight) or PBS (control) was injected i.p. on day 15. 
MC38-bearing mice were administered ansamitocin P3 
(0.3 mg/kg i.v.) on days 16, 17, and 18 after tumor chal-
lenge, alone or combined with anti-Ctla4/anti-PD1 anti-
bodies (250 μg each administered i.p. on days 20, 22, 25, 
and 28). anti-Ctla4/anti-PD1 antibodies administered 
without ansamitocin P3 were given on days 16, 18, 21, and 
24. tumor growth was measured every second day and vol-
ume calculated according to the formula: D/2*d2 with D 
and d being the longest and shortest tumor diameter in mm, 
respectively. Mice were euthanized when tumors reached a 
size of 1,500 mm3.
analysis of tumor-infiltrating lymphocytes
Seven- to ten-week-old mice were injected s.c. into the 
right flank with 5 × 105 MC38 tumor cells in 100 μl 
phenol red-free DMeM. ansamitocin P3 (0.3 mg/kg on 
days 16, 17, and 18) was given alone or combined with 
anti-Ctla4/anti-PD1 (250 μg each i.p. on days 20, 22, 
and 24). Mice receiving antibodies alone were treated on 
days 16, 18, and 20. On day 26, tumors were digested as 
described previously for epithelial sheets and single-cell 
suspensions analyzed by flow cytometry. For detection of 
IFn-γ-producing cells, single-cell preparations were cul-
tured overnight in the presence of anti-CD3/CD28 antibod-
ies and Monensin (Biolegend).
Statistics
T cell proliferation and DC activation marker expression 
were compared using two-tailed paired Student’s t test. 
Kaplan–Meier survival plots were analyzed using a log 
rank test (Mantel-Cox). P < 0.05 was considered significant 
for all tests.
Results
Microtubule-depolymerizing compounds stimulate CD86 
expression in DCs
therapeutic agents investigated included microtubule-stabi-
lizing (paclitaxel, patupilone a/B, docetaxel, D-64131) and 
microtubule-destabilizing (Vinca alkaloids, combretastatin-
a4-phosphate, ansamitocin P3) agents, COX inhibitors 
(naproxen, celecoxib), the angiokinase inhibitor BIBF1120, 
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the angiotensin-converting enzyme inhibitor enalapril, the 
nitric oxide synthase inhibitor I-nMMa, the Dna repli-
cation blocker gemcitabine, the alkylating agent mafos-
famide, the receptor tyrosine kinase inhibitor sunitinib, 
and the histone deacetylase inhibitor SaHa. to delineate 
which of these compounds could induce DC maturation, 
primary murine SP37a3 splenic DCs and human moDCs 
were incubated with drugs at concentrations ranging from 1 
to 0.0001 μM. Cell viability and expression of CD86 were 
assessed by flow cytometry after 24 h as shown for a drug 
concentration of 0.1 μM in Fig. 1. ansamitocin P3 (red) 
was by far the most potent inducer of CD86 on murine and 
human DCs. Cell viability was only modestly affected at 
this drug concentration. Of note, all microtubule-destabi-
lizing agents (blue/red) displayed a pronounced capacity to 
up-regulate CD86 on DCs, in contrast to microtubule-stabi-
lizing agents (green) and compounds of other classes.
ansamitocin P3 triggers phenotypic and functional 
maturation of murine DCs in vitro and in vivo
to determine whether ansamitocin P3 induced the full 
spectrum of phenotypic maturation markers on DCs, 
SP37a3 DCs were incubated with ansamitocin P3 for 24 h. 
Subsequently, the expression of CD80, CD86, CD40, and 
MHCII was measured. Compared with untreated controls, 
ansamitocin P3 significantly increased expression of all 
DC maturation markers (Fig. 2a). In addition, we noted an 
increased production of the pro-inflammatory cytokines 
Il-1β, Il-6, and Il-12 determined by elISa (left panels) 
and by intracellular cytokine staining as detected by flow 
cytometry (right panels; Fig. 2b). expression of the co-
stimulatory molecules CD80 and CD86 as well as produc-
tion of all three cytokines was induced to a similar degree 
by ansamitocin P3 and lPS on SP37a3 DCs. accordingly, 
we found a similar up-regulation of maturation markers and 
cytokines in mouse BMDCs treated with ansamitocin P3 
(Supplementary Figure 1a, B). Furthermore, ansamitocin 
P3 induced in vivo maturation of skin langerhans cells 
(lCs) in the ears of C57Bl/6 mice (Fig. 2c, d). epidermal 
sheets prepared 24 h after injection of 4 μg ansamitocin 
P3 exhibited increased induction of CD86 and increased 
expression of MHCII compared with controls. Immuno-
fluorescence additionally revealed an enlarged cell size and 
altered DC morphology such as elongation of dendrites and 
a decrease in lC density, which may indicate migration of 
lCs to draining lns.
to investigate whether ansamitocin P3-matured DCs 
displayed enhanced antigen-presenting capacity and activa-
tion of T cells in vitro, CD4+ Ot-II T cells were co-cultured 
with SP37a3 DCs, which were pulsed with full-length 
endotoxin-free OVa protein and subsequently treated with 
ansamitocin P3. Flow cytometry revealed that ansamitocin 
P3-treated DCs triggered strong proliferation of T cells, 
comparable to the effect observed with lPS pre-treatment 
(Fig. 2e), which underscores the potential of ansamitocin 
Fig. 1  Identification of ansamitocin P3 as potent inducer of DC 
maturation in vitro. SP37a3 murine DCs and human moDCs were 
incubated with the indicated chemotherapeutic compounds (0.1 μM) 
for 24 h. expression of CD86 on murine SP37a3 DCs and human 
moDCs after exposure to chemotherapeutic agents was correlated 
with viability (left and middle panel). Mean fluorescence intensity 
(MFI) fold change in murine SP37a3 DCs versus MFI fold change in 
human moDCs is shown in the right panel. MFI was assessed by flow 
cytometry; graphs show fold change of MFI compared with mock-
treated cells, which were set as 1. Data are representative of two inde-
pendent experiments with similar results
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P3 to boost antigen-specific T cell responses). Similarly, 
ansamitocin P3-treated, OVa protein-loaded BMDCs 
induced strong proliferation of CD4+ Ot-II T cells as well 
as CD8+ Ot-I T cells (Supplementary Figure 1C). Minimal 
T cell proliferation was seen with protein-loaded untreated 
DCs, indicating that ansamitocin P3 does not interfere 
with antigen processing and presentation by DCs. these 
data indicate that ansamitocin P3-treated DCs efficiently 
A
B
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E
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process and present antigens on both MHC class II and 
class I, and the latter pathway is commonly referred to as 
cross-presentation.
ansamitocin P3 stimulates ln homing of tumor-resident 
DCs and activates T cells in vivo
Migration of primed DCs to tumor-draining lns and subse-
quent activation of antigen-specific T cells are critical steps 
in the establishment of an effective anti-tumor immune 
response [9]. to determine the migratory potential of 
ansamitocin P3-treated tumor-resident DCs, FItC-labeled 
dextran (FItC-Dx), a high-molecular-mass carbohydrate, 
was used as model antigen. FItC-Dx is endocytosed in 
an early phase of DC activation [22]. FItC-Dx with either 
ansamitocin P3 or vehicle was injected into established 
s.c. eg-7 tumors and tumor-draining lns were examined 
for the presence of FItC+ DCs after 48 h by flow cytom-
etry. Significantly more ln-resident DCs were FItC-Dx/
CD86-positive in ansamitocin P3-treated mice (20 %) com-
pared with vehicle control-treated mice (0.3 %; Fig. 3a, b). 
FItC-Dx-bearing DCs were not detected in non-tumor-
draining lns in either case, arguing for local, tumor-selec-
tive effects of ansamitocin P3 treatment (data not shown). 
enhanced activation of antigen-specific T cells in the pres-
ence of ansamitocin P3 was confirmed in vivo: transgenic 
CD8+ and CD4+ T cells specific for OVa isolated from 
Ot-I to Ot-II mice, respectively, were adoptively trans-
ferred into ly5.1 congenic recipient mice, which were 
immunized with a weak agonist peptide derived from the 
original OVa peptide SIInFeKl for Ot-I T cells [20] and 
the natural OVa323–339 peptide for Ot-II i cells together 
with ansamitocin P3, lPS, or vehicle (PBS). Both ansami-
tocin P3 and lPS effectively induced strong proliferation 
of Ot-I and Ot-II T cells after 3 days (Fig. 3c).
Human DCs stimulated by ansamitocin P3 undergo 
maturation and activate allogeneic T cells
to investigate the stimulatory effects of ansamitocin P3 
on human DCs, monocyte-derived DCs were exposed to 
ansamitocin P3 and analyzed for up-regulation of Hla-
Dr and the co-stimulatory molecules CD86, CD83, and 
CD40. Similar to murine DCs, ansamitocin P3 treatment 
up-regulated expression of all four maturation markers 
on human moDCs in a concentration-dependent fashion 
(Fig. 4a), while DC viability was not significantly affected 
by ansamitocin P3 at the indicated concentrations, as deter-
mined by Sytoxgreen® staining (data not shown). to test 
moDC functionality in mixed lymphocyte cultures, ansami-
tocin P3-treated moDCs were co-cultured with allogeneic 
CD8+ T cells (DC/T cell ratio of 1:25). ansamitocin P3 or 
lPS pre-treated DCs significantly increased T cell prolif-
eration compared with untreated moDC controls (Fig. 4B).
therapeutic efficacy of ansamitocin P3 is dependent 
on CD11c+ DCs, interferon-γ, and adaptive immune cells
Both innate and adaptive immunity critically contribute 
to treatment outcomes of several chemotherapeutic com-
pounds such as anthracyclines and histone deacetylase 
inhibitors [23, 24]. to determine the importance of the 
adaptive immune system (mainly T and B cells) and IFn-γ 
for the treatment efficacy of ansamitocin P3, mice bearing 
s.c. eg-7 tumors (~80 mm3) were injected intratumorally 
with ansamitocin P3 (0.3 mg/kg). ansamitocin P3 signifi-
cantly delayed tumor growth in syngeneic immunocompe-
tent Wt C57Bl/6 mice compared with controls, whereas 
in immune-deficient rag2−/− or IFn-γr−/− mice this effect 
was clearly reduced (Fig. 5a), a finding that directly impli-
cates an involvement of the adaptive immune system in the 
growth inhibitory effects of ansamitocin P3.
to confirm that DCs are indeed required for tumor 
growth inhibition upon ansamitocin P3 treatment, we 
depleted CD11c+ cells using CD11c-Dtr/gFP mice [25]. 
Wt and CD11c-Dtr/gFP mice bearing 3ll-thy1.1-
OVa tumors were treated with Dt with or without ansami-
tocin P3. tumor growth suppression by ansamitocin P3 in 
CD11c+ DC-depleted mice was significantly reduced com-
pared with similarly treated Wt mice (Fig. 5b). these data 
suggest that DCs are critically required for the anti-tumor 
effects of ansamitocin P3 against solid malignancies.
Fig. 2  ansamitocin P3 induces phenotypic and functional matura-
tion of SP37a3 murine DCs and enhances stimulation of antigen-
specific T cells. a expression of MHCII and the co-stimulatory 
molecules CD80, CD86, and CD40 by SP37a3 murine DCs after 
exposure (24 h) to ansamitocin P3 (0.1 μM) or lPS (500 ng/ml) 
as positive control. Data show one histogram representative of at 
least five independent experiments. b Secretion of Il-1β, Il-6, and 
Il-12 was assessed in supernatants from cultures as described in (a) 
using elISa (left panels) as well as by intracellular cytokine stain-
ing for flow cytometry detection (right panels). c + d ansamitocin 
P3 (4 μg/animal) or vehicle alone was injected intradermally into the 
ears of C57Bl/6 mice (four mice per group, two ears per point). ear 
skin specimens were harvested 24 h later, and epidermal sheets were 
either fixed in acetone, stained for MHCII (red) and CD86 (green), 
and analyzed by immunofluorescence c, or enzymatically digested 
and stained for CD45, CD11c, MHCII, and CD86 for flow cytomet-
ric analysis d. Data show the mean (n = 2) of % CD86high cells and 
MFI of CD86 within the CD45+CD11c+MHCII+ population per data 
point. Control indicates mock-treated mice. three experiments were 
performed with similar results. Mean ± SD of one representative 
experiment is shown. e Pre-treatment of murine SP37a3 DCs with 
ansamitocin P3 induced enhanced activation of antigen-specific T 
cells. DCs were loaded with OVa protein and treated with ansami-
tocin P3 (0.01 μM) or lPS (500 ng/ml) prior to irradiation and addi-
tion to microcultures of CD4+ Ot-II T cells. the DC/T cell ratio is 
indicated. Proliferation of Ot-II T cells was assessed by flow cytom-
etry. Data show representative histograms from one of at least three 
independent studies
◂
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therapeutic synergy of ansamitocin P3 with blockade 
of PD-1/Ctla-4 inhibitory pathways results in improved 
intratumoral T cell effector function
given the critical role of adaptive immunity for the efficacy 
of ansamitocin P3 treatment, we hypothesized that a combi-
nation of ansamitocin P3 with antibodies blocking the T cell 
checkpoint inhibitors Ctla-4 and PD-1 may provide greater 
therapeutic benefit for the treatment of established tumors 
than single-agent treatment. tumor growth was measured in 
Wt mice bearing subcutaneous MC38 tumors treated with 
ansamitocin P3 alone, anti-PD-1/anti-Ctla-4 antibodies 
alone, or the combination of both (Fig. 5c, d). tumor growth 
was rapid in the control group (0/10 mice were tumor free). 
ansamitocin P3 alone or PD-1/Ctla-4-blocking antibod-
ies alone significantly delayed tumor growth and achieved 
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Fig. 3  DC homing to tumor-draining lns and enhanced in vivo T 
cell responses after ansamitocin P3 treatment. a + b FItC-conju-
gated dextran suspended in vehicle alone (PBS/DMSO), in vehicle 
containing ansamitocin P3 (4 μg per mouse) was injected intratu-
moral into C57Bl/6 mice with established s.c. eg-7 tumors. Forty-
eight hour later, tumor-draining lns were examined for the presence 
of FItC-labeled dextran-bearing DCs (CD45+CD11c+MHCII+) 
by flow cytometry. a representative dot plots depict FItC+ DCs 
detected in tumor-draining lns after PBS/DMSO (left) or ansami-
tocin P3 (right) injection. b Graphs summarize percent of FItC+ 
DCs from one experiment; representative results from one of three 
experiments are shown. c eFluor670-labeled T cells from lns of 
naïve Ot-I or Ot-II transgenic mice were adoptively transferred into 
C57Bl/6-ly5.1 recipient mice. after 24 h, mice were immunized via 
tail-base injection of 25 μg OVa-t4 peptide (SIItFeKl) or 5 μg 
OVa323–339 peptide in the absence (PBS/DMSO) or presence of matu-
ration stimuli [ansamitocin P3 (4 μg per mouse), or lPS (25 μg per 
mouse)]. Proliferation of donor-derived Ot-I CD8+ and Ot-II CD4+ 
T cells was assessed 4 days after adoptive transfer by flow cytometric 
analysis of single-cell suspensions from inguinal, “vaccine”-draining 
lns. c Histograms show data from one representative experiment. 
the experiment was performed independently two times with com-
parable results
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complete eradication of tumors in 1/12 and 4/12 mice, 
respectively. Importantly, a strong synergism was seen with 
combination treatment (tumor eradication in 9/11 mice).
to further delineate this synergy, we analyzed the change 
in the composition as well as functionality of tumor-infiltrat-
ing immune cells, in particular considering the frequency of 
CD4+CD25+FoxP3+ tregs [26] and the intratumoral effec-
tor T cell to treg ratio [27]. to this end, tumor-bearing mice 
were treated with ansamitocin P3 alone, anti-PD-1/Ctla-4 
antibodies alone, or the combination of both, and tumor-infil-
trating immune cells were analyzed (Fig. 6a). In particular 
for the latter group, we observed a decrease in the percentage 
of tumor-infiltrating CD4+CD25+FoxP3+ treg cells, while 
IFn-γ producing infiltrating CD4+ and CD8+ effector T cells 
substantially increased (Fig. 6b, c). this resulted in a shift 
from a low to high effector to t regulatory cell ratio upon 
treatment with the combination therapy. CD11b+F4/80+ 
tumor-associated macrophages (taM) are a distinct popula-
tion of infiltrating myeloid cells, which are capable of pro-
moting tumor growth and angiogenesis [28]. We observed a 
decrease of CD11b+ly6C−F4/80+ taMs in both CD45+ and 
CD11b+ populations upon treatment with ansamitocin P3, 
which was even more pronounced in the combination group. 
Overall, the changes in the intratumoral effector T cell to treg 
ratio and the abundance of CD11b+ly6C−F4/80+ taMs, 
which reflect a shift toward an immunologically permissive 
microenvironment, provide a mechanistic explanation of the 
therapeutic efficacy of the combination therapy.
Discussion
In this study, we demonstrate that both adaptive and 
innate immunity are critically required for the therapeutic 
A
B
*** 
Fig. 4  ansamitocin P3-treated human DCs up-regulate co-stimu-
latory molecules and display an enhanced T-cell stimulatory capac-
ity. a Concentration-dependent expression of CD86, CD83, CD40, 
and Hla-Dr after 24 h exposure of human moDCs to ansamitocin 
P3 or lPS (500 ng/ml) was assessed by flow cytometry. MFI change 
compared with mock-treated cells, which were set as 1, is shown 
(left panel). all data are representative of at least three independent 
experiments. Data are depicted as mean ± SD. representative histo-
grams for CD83, CD86, CD40, and Hla-Dr expression are shown 
(right panel). Control cells were incubated with vehicle alone. b 
Monocyte-derived DCs were exposed to ansamitocin P3 or lPS and 
subsequently used to stimulate allogeneic CD8+ T cells in a mixed 
lymphocyte reaction. T cell proliferation was measured after 4 days. 
the experiments were repeated with PBMCs from eight healthy 
blood donors yielding similar results (left panel). representative flow 
cytometry plots of one experiment are shown (right panel)
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anti-tumor efficacy of ansamitocin P3, a structural analog 
of maytansine [29–31]. Maytansine derivatives are tubulin-
binding agents, which have shown significant activity in 
various cancer types. though systemic administration of 
free maytansinoids has demonstrated substantial toxicity, 
the wide therapeutic index of antibody–drug conjugates 
(aDCs) has lead to the exploration of maytansine deriva-
tives as cytotoxic payloads of aDCs, which allows a tumor-
targeted delivery, a key determinant of clinical activity and 
tolerability [32]. In addition, the development of synthetic 
derivatives of maytansine has been instigated that pos-
sess a 100- to 1,000-fold higher cytotoxic potency than 
clinically used anticancer drugs such as Vinca alkaloids 
[33]. While trastuzumab emtansine (t-DM1) has recently 
been approved in Her2-positive breast cancer, maytansi-
noid-conjugated antibodies such as Bt062, Sar3419, 
BaY94-9343, and IMgn529 are currently under clinical 
evaluation in phase I/II protocols [34]. Here, we report that 
ansamitocin P3 induces a potent phenotypic and functional 
maturation of both murine and human DC populations. 
Consequently, ansamitocin P3 exposed DCs displayed 
an enhanced capacity to activate T cells both in vitro and 
in vivo. Of note, these effects have been observed even 
in the absence of tumor cell death. Maturation of DCs in 
Fig. 5  the efficacy of ansami-
tocin P3 treatment is dependent 
on CD11c+ DCs, IFn-γ, and 
adaptive immunity and syner-
gizes with antibody-mediated 
blockade of T cell inhibitory 
receptors PD-1 and Ctla-4. a 
Wt, rag2−/−, and IFn-γr−/− 
mice bearing s.c. eg-7 tumors 
received intratumoral injections 
of ansamitocin P3 (0.3 mg/
kg) or vehicle (PBS). b tumor 
(3ll-thy1.1-OVa) growth 
in Wt and CD11c-Dtr/gFP 
mice upon treatment with 
ansamitocin P3. Dt was used 
for depletion of CD11c+ cells 
in CD11c-Dtr/gFP mice. PBS 
or PBS + Dt was injected in 
control mice. results represent 
pooled data from two independ-
ent experiments. c ansamitocin 
P3 (0.3 mg/kg), anti-PD-1/anti-
Ctla-4 mabs, or the combina-
tion of both was administered in 
C57Bl/6 mice bearing 16-day 
established subcutaneous MC38 
tumors. treatment schedule is 
detailed in the materials and 
methods section. Control tumor-
bearing mice received matched 
isotype control antibodies. 
results represent pooled data 
from two independent experi-
ments and are depicted as (c) 
individual tumor growth curves 
or d cumulative tumor volume 
over time and as a Kaplan–
Meier survival plot
C
D
A B WT: Control
WT: DT
WT: DT + AnsP3
CD11c-DTR: DT
CD11c-DTR: DT + AnsP3
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vivo resulted in extensive homing of tumor-resident DCs 
to the tumor-draining lymph node. although ansamitocin 
P3 exerts direct cytotoxic effects on tumor cells, its thera-
peutic efficacy critically required an intact immune system. 
In particular, utilizing depletion experiments, we showed 
that the anti-tumor effect in vivo was largely dependent 
on CD11c+ DCs. to the best of our knowledge, this report 
is the first to demonstrate that ansamitocin P3 exerts an 
immunostimulatory function, mainly by modulating the 
anti-tumor immune response through activation of DCs.
In our initial analysis of a broad panel of cytotoxic com-
pounds, we recognized that most notably microtubule-tar-
geting agents were able to induce maturation of DCs. the 
observed effect was particularly pronounced for microtu-
bule-destabilizing agents and associated with substantial 
up-regulation of maturation markers such as CD86 in both 
human and murine DCs. this observation is consistent with 
data from a functional screen of chemotherapeutic agents, 
which identified microtubule-targeting agents as inducers 
of DC maturation [14]. Microtubules play key roles in cell 
proliferation, trafficking, signaling, and migration in eukar-
yotic cells and are targeted by several anticancer therapies. 
Microtubule-destabilizing compounds include colchicine, 
the Vinca alkaloids and maytansines. In contrast to micro-
tubule-stabilizing agents, which mainly bind at the taxane 
pocket [35], the binding site of ansamitocin P3 on β-tubulin 
partially overlaps with the vinblastine-binding site [36]. 
Both classes, microtubule-stabilizing and microtubule-
destabilizing agents interfere with microtubule dynamics 
leading to tumor cell apoptosis. It is, however, currently 
unclear whether their disparate mode of action explains 
our observed difference in DC activation. along the same 
line, and contrasting our findings with ansamitocin P3 in 
DCs, paclitaxel has been reported to reduce the capac-
ity for endocytosis and production of pro-inflammatory 
cytokines, thus inhibiting anti-tumor immune responses 
[37]. although signaling pathways in DCs remain incom-
pletely understood the microtubule-interfering agents, vin-
blastine and taxol were shown to evoke distinct signaling 
through c-Jun/aP-1-dependent and c-Jun/aP-1-independ-
ent mechanisms, despite a common activation of the JnK 
pathway [38]. Further studies are clearly necessary to accu-
rately define signaling pathways and monitor microtubule 
dynamics in DCs upon exposure to immunostimulatory 
microtubule inhibitors such as ansamitocin P3.
Dendritic cells (DCs) are an integral component of the 
tumor-specific immune response due to their capacity to 
capture, process, and present tumor-derived antigens to T 
cells [39]. tumors, however, may interfere with DC mat-
uration and function and promote tumor growth through 
generation of “pro-tumorigenic DCs” [40–42]. Our findings 
demonstrate that ansamitocin P3 is capable to induce matu-
ration and migration of intratumoral DCs to the draining 
ln, thereby rewiring these cells into anti-tumor DCs. Con-
sequently, functional tumor antigen-specific T cells are pro-
moted, which in turn may contribute to tumor rejection. In 
contrast to direct effects on DCs using low non-toxic con-
centrations of cytotoxic drugs, we have observed effects on 
DC maturation and T cell activation over a wide range of 
ansamitocin P3 doses with the highest doses being capa-
ble of inducing tumor cell apoptosis in vitro and in vivo. 
It remains to be determined, which subset of antigen-pre-
senting cells is instrumental in ansamitocin P3 induced 
immunoactivation in vivo. Ma et al. have previously dem-
onstrated that intratumoral CD11c+CD11b+ly6Chi cells, 
which exhibit some characteristics of inflammatory DCs 
[43], are required for the efficacy of anthracycline-based 
chemotherapy [44]. Our data do not exclude the possibil-
ity that malignant cells, which undergo cell death upon 
injection of ansamitocin P3, release signals, which fur-
ther amplify the anti-tumor immune response. Distinct 
molecular mediators either exposed on the cell surface or 
released into the extracellular space have been associated 
with immunogenic cell death induced by anthracyclines as 
well as oxaliplatin [8]. Such molecular mediators include 
calreticulin, atP, and high-mobility group box 1 (HMgB1) 
[8]. although we have demonstrated pronounced activation 
of OVa-specific CD8+ and CD4+ T cells in the absence 
of tumor cell death, further investigations are necessary to 
explore the precise molecular events induced by ansami-
tocin P3.
Impressive clinical success has been achieved by 
novel cancer immunotherapies that target immunoregula-
tory checkpoints on T cells [45–47]. Only recently and 
in accordance with preclinical data from a murine B16 
melanoma model [48], unprecedented clinical benefits 
with rapid and deep responses have been reported with 
concurrent Ctla-4/PD-1 blockade [3]. Our data sug-
gest that upon treatment with ansamitocin P3, specific T 
cell responses are augmented, which may be potentially 
rendered dysfunctional in tumor-bearing hosts. We thus 
explored a functional interplay between ansamitocin P3 
and Ctla-4/PD-1 blocking antibodies. Indeed, the com-
bination was significantly more potent against established 
tumors than ansamitocin P3 or antibodies alone. reflect-
ing the therapeutic benefit of the combination, we demon-
strated a significant decrease in the percentage of tumor-
resident tregs and increase in IFn-γ-producing T effector 
cells. In addition, we noticed a significant decrease in the 
proportion taM, which are often pro-tumorigenic [49].
Our study identifies a novel mechanism of immune 
engagement by ansamitocin P3 in tumor-bearing hosts 
through triggering functional maturation of DCs. this is 
of clinical relevance as the excitement over antibody–may-
tansinoid conjugates is steadily building, and this class of 
drugs is readily integrated into the treatment regimen of 
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cancer patients. Moreover, using Ctla-4/PD-1-blocking 
antibodies in combination with ansamitocin P3, we have 
identified a potent novel therapeutic strategy, which war-
rants further investigation into preclinical models and early 
clinical trials.
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